메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Until 1985 growth hormone (GH) was obtained from pituitary extracts, and wasavailable in limited amounts only to treat severe growth hormone deficiency (GHD). With the availability of unlimited quantities of GH obtained from recombinant DNAtechnology, researchers started to explore new modalities to treat GHD children,as well as to treat a number of other non-GHD conditions. Although with somedifferences between different countries, GH treatment is indicated in children withTurner syndrome, chronic renal insufficiency, Prader-Willi syndrome, deletions/mutations of the SHOX gene, as well as in short children born small for gestationalage and with idiopathic short stature. Available data from controlled trials indicatethat GH treatment increases adult height in patients with Turner syndrome, inpatients with chronic renal insufficiency, and in short children born small forgestational age. Patients with SHOX deficiency seem to respond to treatmentsimilarly to Turner syndrome. GH treatment in children with idiopathic short statureproduces a modest mean increase in adult height but the response in the individualpatient is unpredictable. Uncontrolled studies indicate that GH treatment may bebeneficial also in children with Noonan syndrome. In patients with Prader-Willisyndrome GH treatment normalizes growth and improves body composition andcognitive function. In any indication the response to GH seems correlated to thedose and the duration of treatment. GH treatment is generally safe with no majoradverse effects being recorded in any condition.

목차

등록된 정보가 없습니다.

참고문헌 (23)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0